Genmab — Januar 2020
-
The CD38low natural killer cell line KHYG1 transiently expressing
CD16F158V in combination with daratumumab targets multiple
myeloma cells with minimal efector NK cell fratricide https://sci-hub.tw/https://link.springer.com/article/10.1007/s00262-019-02477-8 -
so
we are not the only ones thinking that Dara should be added to the drinking water
https://twitter.com/IMFjimMYELOMA/status/1215669209058799616 -
Future Direction of CD38 Antibodies in Multiple Myeloma https://www.youtube.com/watch?v=d6s2jqaafL0
-
Case 2: Overcoming High Risk in Myeloma https://www.youtube.com/watch?v=nCWXvR7kOz8
-
-
Thx E L. In this one she says that Isa doesn't need as much pre-medication as dara. https://www.targetedonc.com/investigator-perspectives/target-cd38-rr-mm/icaria-mm-phase-iii-trial-overview
-
-
Det trog jeg ikke du kan konkludere
-
Jeg Thor mere på at JNJ endnu ikke har givet Genmab besked
-
tror
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
